ArticlePloS one2026

Efficacy and safety of immune checkpoint inhibitors combined with TKIs for recurrent or metastatic cervical cancer with PIK3CA mutation.

Lele Chang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.